| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $115.9M | -13.2% |
| SG&A Expense | $29.7M | -12.1% |
| Operating Income | -$93.5M | +19.5% |
| Pre-tax Income | -$83.2M | +19.3% |
| Income Tax | $1.4M | +115.3% |
| Net Income | -$84.7M | +9.7% |
| EPS (Basic) | -$2.00 | +10.3% |
| EPS (Diluted) | -$2.00 | +10.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $84.7M | -23.9% |
| Short-term Investments | $68.1M | -39.4% |
| Current Assets | $171.1M | -29.8% |
| Total Assets | $176.5M | -30.5% |
| Current Liabilities | $25.3M | -35.3% |
| Total Liabilities | $25.4M | -39.3% |
| Stockholders' Equity | $151.1M | -28.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$76.4M | +39.9% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $49.5M | -36.6% |
| Financing Cash Flow | $542K | -35.6% |
| Free Cash Flow | -$76.4M | +40.8% |